VBIO news

Valion Bio showed no toxicity in a government-funded Entolimod study. This safety data de-risks the drug development and supports moving toward a planned efficacy trial.

Interim CEO Dean Zikria prioritizes advancing Entolimod, pursuing commercial capabilities at CDMO Velocity, and evaluating strategic deals to address undervaluation.

Valion Bio's CDMO unit emphasizes U.S. domestic manufacturing following Section 232 tariffs. This strategic positioning is relevant as the Company views domestic capabilities as essential for the development and supply of its Entolimod candidate.

Valion Bio appointed Thomas Jensen as Board Chair and outlined his perspectives on advancing Entolimod, emphasizing the company's strong foundation and the lack of approved treatments for acute radiation syndrome.

Valion Bio and Shear Kershman Laboratories announced a successful oral formulation for Entolimod, marking a new needle-free delivery pathway that could expand the company's market opportunity.

The company demonstrated a 200-fold manufacturing scale-up and initiated studies for oncology supportive care. These strategic developments actively expand Valion Bio's biomanufacturing capabilities and broaden its platform beyond biodefense into cancer treatment.

Valion Bio's board and shareholders approved a second amendment to the 2021 Equity Incentive Plan, increasing authorized shares from 637,958 to 3,219,566 shares effective May 28, 2026. The plan includes annual automatic increases of up to 5% of outstanding shares through January 1, 2031, providing e…